Methods for assessing comorbidity and its role in patients with cardiac pathology
DOI:
https://doi.org/10.21638/spbu11.2023.201Abstract
There are several different definitions of the combination of multiple nosology within one organism: comorbidity, multimorbidity, syntropy, and dystropy, etc. Comorbidity is an important component of pathophysiological processes, which has a significant impact on the course and outcome of cardiac diseases in patients. Therefore, in recent decades, researchers have been actively engaged in the problem of assessing the degree of contribution of comorbidity to the overall state of the body. For this purpose, a number of scales and indices of comorbidity have been developed, which allow estimating the burden of comorbidity on the underlying disease within certain groups of diseases. Consideration of comorbidity in routine clinical practice allows to increase reliable prognostic assumptions and correctly build a therapeutic strategy. As a result, it improves patients’ quality of life, allows them to achieve favorable outcomes, and most effectively prevents complications in patients with comorbidity. The assessment of comorbidity in cardiological, endocrinological, oncological, and neurological pathologies is particularly important, since they have the most general negative effect on the entire patient’s body.
Keywords:
polymorbidity, comorbidity, cardiology, systemic diseases, pathophysiology, comorbidity indices, rating scales
Downloads
Download data is not yet available.
References
Литература
Лазебник Л. Б., Конев Ю. В. Исторические особенности и семантические трудности использования терминов, обозначающих множественность заболеваний у одного больного // Экспериментальная и клиническая гастроэнтерология. 2018. Т. 154, № 6. C. 4–9.
Белялов Ф. И. Лечение болезней в условиях коморбидности. М.: ГЭОТАР-Медиа, 2022. 560 c.
Вяткин В. Б. Об использовании термина «синтропия» в научных исследованиях // Научное обозрение. Реферативный журнал. 2016. № 3. С. 81–84.
Мамедов М. Н. Возможны ли диагностика и лечение метаболического синдрома в реальной практике? // Лечащий врач. 2006. № 6. С. 34–39.
Крылов А. А. К проблеме сочетаемости заболеваний // Клиническая медицина. 2000. № 1. С. 56–63.
Puzyrev V. P. Genetic bases of human comorbidity // Russ. J. Genet. 2015. Vol. 51, no. 4. P. 408–417.
Kuan V., Denaxas S., Patalay P., Nitsch D., Mathur R., Gonzalez-Izquierdo A., Sofat R., Partridge L.,Roberts A., Wong I. C. K., Hingorani M., Chaturvedi N., Hemingway H., Hingorani A. D. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study // Lancet Digit. Health. 2023. Vol. 5, no. 1. P. e16–e27.
Наумова Л. А., Осипова О. Н. Коморбидность: механизмы патогенеза, клиническое значение// Современные проблемы науки и образования. 2016. № 5. С. 112-121.
Лазебник Л. Б., Верткин А. Л., Конев Ю. В. Старение: профессиональный врачебный подход (Национальное руководство). М.: Эксмо, 2014. 320 с.
Мамедов М. Н., Бадейникова К. К., Каримов А. К. Мишени для профилактики коморбидности сердечно-сосудистых и онкологических заболеваний // Российский кардиологический журнал.2022. Т. 27, № 11. С. 115–120.
Старичкова А. А., Цыганкова О. В., Хидирова Л. Д., Старичков А. А., Литвиненко П. И. Кардиометаболические нарушения при SARS-CoV-2-инфекции и постковидном синдроме // Лечащий врач. 2022. № 3 (25). С. 49–58.
Рублев В. Ю., Гельцер Б. И., Сергеев Е. А., Котельников В. Н., Карпов Р. С. Коморбидность ишемической болезни сердца и еe значение в прогнозировании результатов аортокоронарного шунтирования // Бюллетень сибирской медицины. 2022. Т. 21, № 1. С. 152–161.
Куценко М. А., Чучалин А. Г. Парадигма коморбидности: синтропия ХОБЛ и ИБС // РМЖ. 2014. Т. 5. С. 389.
Gurigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A. R., Lancellotti P., Patel A., DeCara J., Mitchell J., Harrison E., Moslehi J., Witteles R., Calabro M. G., Orecchia R., de Azambuja E., Zamorano J. L., Krone R., Iakobishvili Z., Carver J., Armenian S., Ky B., CardinaleD., Cipolla C. M., Dent S., Jordan K. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations // Annals of Oncology. 2020. Vol. 31, no. 2.P. 171–190.
Белялов Ф. И. Выбор и классификация лекарственных препаратов при коморбидных заболеваниях // Архивъ внутренней медицины. 2020. Т. 10, № 1. С. 161–169.
Ширинский В. С., Ширинский И. В. Коморбидные заболевания — актуальная проблема клинической медицины // Сибирский журнал клинической и экспериментальной медицины. 2014.T. 29, № 1. C. 7–12.
Губанова Г. В., Беляева Ю. Н., Шеметова Г. Н. Коморбидный пациент: этапы формирования,факторы риска и тактика ведения // Современные проблемы науки и образования. 2015. T. 6.C. 60–77.
Белялов Ф. И. Двенадцать тезисов коморбидности // Клиническая медицина. 2009. Т. 87, № 12.P. 69–71.
Gijsen R., Hoeymans N., Schellevis F. G., Ruwaard D., Satariano W. A., van den Bos G. A. Causes and consequences of comorbidity: A review // J. Clin. Epidemiol. 2001. Vol. 54, no. 7. P. 661–674.
Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine // Evidence Based Medicine. 2010. Vol. 15, no. 6. P. 165.
Губанова Г. В., Беляева Ю. Н., Шеметова Г. Н. Коморбидный пациент: этапы формирования,факторы риска и тактика ведения // Современные проблемы науки и образования. 2015. Т. 6. C. 60–77.
De Groot V., Beckerman H., Lankhorst G. J., Bouter L. M. How to measure comorbidity: A critical review of available methods // J. Clin. Epidemiol. 2003. Vol. 56, no. 3. P. 221–229.
Mark D., Miller M. D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg: University of Pittsburgh, 1991. 31 p.
Deyo R. A., Cherkin D. C., Ciol M. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases // J. Clin. Epidemiol. 1992. Vol. 45, no. 6. P. 613–619.
Kaplan M. H., Feinstein A. R. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus // Diabetes. 1973. Vol. 22, no. 3. P. 74–160.
Greenfield S., Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip replacement // Med. Care. 1993. Vol. 31. P. 141–154.
Rozzini R., Frisoni G. B., Rozzini R. GeriatricIndex of Comorbidity: validation and comparison with other measures of comorbidity // Age Ageing. 2002. Vol. 31, no. 4. P. 85–277.
Groll D. L., To T., Bombardier C., Wright J. G. The development of a comorbidity index with physical function as the outcome // J. Clin. Epidemiol. 2005. Vol. 58, no. 6. P. 595–602.
Preedy V. R., Watson R. R. Handbook of Disease Burdens and Quality of Life Measures. New York:Springer, 2010, 4507 p.
Litwin M. S., Greenfield S., Elkin E. P. Assessment of Prognosis with the Total Illness Burden Index for Prostate Cancer // Cancer. 2007. Vol. 109, no. 9. P. 83–177.
Hall S. F. What is best comorbidity index for retrospective survival studies in head and neck oncology.Toronto: [s. n.], 2001. 135 p.
Захарова Е. Ю., Севрук Т. В., Устинова И. Б., Красько О. В. Прогностическое значение глобальной продольной деформации у пациентов с гипертрофической кардиомиопатией // Российский кардиологический журнал. 2018. № 2. С. 7–12.
Komajda M., Cosentino F., Ferrari R., Kerneis M., Kosmachova E., Laroche C., Maggioni A. P., Rittger H.,Steg P. G., Szwed H., Tavazzi L., Valgimigli M., Gale C. P. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry // Eur. J. Prev. Cardiol. 2021. Vol. 28, no. 4. P. 432–445.
Van Manen J. G., Korevaar J. C., Dekker F. W., Boeschoten E. W., Bossuyt P. M., Krediet R. T.How to adjust for comorbidity in survival studies in ESRD patients: A comparison of different indices // American Journal of Kidney Diseases. 2002. Vol. 40, no. 1. P. 82–89.
Hemmelgarn B. R., Manns B. J., Quan H., Ghali W. A. Adapting the Charlson comorbidity index for use in patients with ESRD // American Journal of Kidney Diseases. 2003. Vol. 42, no. 1, Suppl. 2. P. 125–132.
Daly C. A., De Stavola B., Fox K. M. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: Prospective observational study // British Medical Journal. 2006. Vol. 332,no. 7536. P. 262–267.
Bhatt D. L., Steg P. G., Ohman E. M., Hirsch A. T., Ikeda Y., Mas J. L., Goto S., Liau C. S., Richard A. J., Röther J., Wilson P. W.International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis // J. Am. Med. Assoc. 2006. Vol. 295, no. 2. P. 180–189.
Sorbets E., Fox K. M., Elbez Y., Danchin N., Dorian P., Ferrari R., Ford I., Greenlaw N., Kalra P. R., Parma Z., Shalnova S., Tardif J. C., Tendera M., Zamorano J. L., Vidal-Petiot E., Steg P. G. Long-term outcomes of chronic coronary syndrome worldwide: Insights from the international CLARIFY registry// Eur. Heart J. 2020. Vol. 41, no. 3. P. 347–356.
Barbarash O. L., Kashtalap V. V., Shibanova I. A. Cardiovascular comorbidity: Patient with coronary artery disease and peripheral artery atherosclerosis. How to identify and manage the risks of ischemic events? // Rational Pharmacotherapy in Cardiology. 2020. Vol. 16, no. 4. P. 607–613.
Зыков М. В., Дьяченко Н. В., Трубникова О. А., Эрлих А. Д., Кашталап В. В., Барбараш О. Л. Коморбидность и пол пациентов в оценке риска смерти в стационаре после экстренного чрескожного коронарного вмешательства // Кардиология. 2020. Т. 60, № 9. С. 38–45.
Фролова Ю. В., Сысоев С. Ю., Тюрина Е. А., Никода В. В., Зайцев А. Ю., Дымова О. В., Беджанян А. Л. Оценка влияния коморбидной хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка на ведение пожилых онкологических пациентов до и после радикальных оперативных вмешательств // Хирургия. Журнал им. Н. И. Пирогова. 2021.Т. 6, № 2. С. 45–51.
Yeh E. T. H., Bickford C. L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management // Journal of the American College of Cardiology. 2009. Vol. 53, no. 24.P. 2231–2247.
Palumbo A., Rajkumar S. V., Dimopoulos M. A., Richardson P. G., San Miguel J., Barlogie B., HarousseauJ., Zonder J. A., Cavo M., Zangari M., Attal M., Belch A., Knop S., Joshua D., Sezer O., Ludwig H., Vesole D., Bladé J., Kyle R., Westin J., Weber D., Bringhen S., Niesvizky R., Waage A., von Lilienfeld-Toal M., Lonial S., Morgan G. J., Orlowski R. Z., Shimizu K., Anderson K. C., Boccadoro M., Durie B. G., Sonneveld P., Hussein M. A. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma // Leukemia. 2008. Vol. 22, no. 2. P. 414–423.
Korzh A. Cardiorenal syndrome: clinical significance, diagnostic criteria, and principles of treatment// Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini. 2016. Vol. 2. P. 37–42.
Rodrigo E., Pich S., Subirana I., Fernandez-Fresnedo G., Barreda P., Ferrer-Costa C., M. de Francisco Á. L.,Salas E., Elosua R., Arias M. A clinical-genetic approach to assessing cardiovascular risk in patients with CKD // Clin. Kidney J. 2017. Vol. 10, no. 5. P. 672–678.
Easyan A. M. Chronic renal disease: risk factors, early detection, principles of antihypertensive therapy// Medical Council. 2017. No. 12. P. 18–25.
Zueva T., Zhdanov T., Urazlina S. Comorbidity of renal and cardiac pathology // Medical news of the North Caucasus. 2019. Vol. 14, no. 4. P. 711–717.
United States Renal Data System. USRDS Annual Data Report // ESRD in the United States. 2018.Vol. 2. P. 183–598.
Collins A. J., Vassalotti J. A., Wang C., Li S., Gilbertson D. T., Liu J., Foley R. N., Chen S. C., Arneson T. J.Who Should Be Targeted for CKD Screening? Impact of Diabetes, Hypertension, and Cardiovascular Disease // American Journal of Kidney Diseases. 2009. Vol. 53, no. 3. P. 71–77.
Морозова Т. Е., Попова Т. С., Барабанова Е. А., Самохина Е. О. Шкала «коморбидный пациент» как инструмент врача общей практики для повышения приверженности к лечению пациентов,проживающих в сельской местности // Сеченовский вестник. 2021. Т. 11, № 4. С. 50–59.
References
The plurality of diseases in one patient. Experimental and Clinical Gastroenterology. 2018, vol. 154,no. 6, pp. 4–9. (In Russian)
Belyalov F. I. Treatment of diseases in conditions of comorbidity.Moscow, GEOTAR-Media Publ., 2022,560 p. (In Russian)
Vyatkin V. B. On the use of the term “syntropy” in scientific research. Scientific Review. Abstract journal.2016, vol. 3, pp. 81–84. (In Russian)
Mamedov M. N. Is it possible to diagnose and treat metabolic syndrome in real practice? Attending doctor, 2006, no. 6, pp. 34–39. (In Russian)
Krylov A. A. To the problem of compatibility of diseases. Clinical medicine, 2000, vol. 1, pp. 56–63. (In Russian)
Puzyrev V. P. Genetic bases of human comorbidity. Russ. J. Genet., 2015, vol. 51, no. 4, pp. 408–417.
Kuan V., Denaxas S., Patalay P., Nitsch D., Mathur R., Gonzalez-Izquierdo A., Sofat R., Partridge L., Roberts A., Wong I. C. K., Hingorani M., Chaturvedi N., Hemingway H., Hingorani A. D. Identifying and visualizing multimorbidity and comorbidity patterns in patients in the English National HealthService: a population-based study. Lancet Digit. Health, 2023, vol. 5, no. 1, pp. e16–e27.
Naumova L. A., Osipova O. N. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern problems of science and education, 2016, vol. 5, pp. 112–121. (In Russian)
Lazebnik L. B., Vertkin A. L., Konev Yu. V. Aging: a professional medical approach (National guide).Moscow, Eksmo Publ., 2014, 320 p. (In Russian)
Mamedov M. N., Badeinikova K. K., Karimov A. K. Targets for the prevention of comorbidity of cardiovascular and oncological diseases. Russian Journal of Cardiology, 2022, vol. 27, no. 11, pp. 115–120.
Starichkova A. A., Tsygankova O. V., Khidirova L. D., Starichkov A. A., Litvinenko P. I. Cardiometabolic disorders in SARS-CoV-2 infection and post-covid syndrome. Attending physician, 2022, no. 3 (25),pp. 49–58. (In Russian)
Rublev V. Yu., Geltser B. I., Sergeev E. A., Kotelnikov V. N., Karpov R. S. Сomorbidity of coronary artery disease and its significance in predicting the results of coronary artery bypass grafting. Bulletin of Siberian Medicine, 2022, vol. 21, no. 1, pp. 152–161. (In Russian)
Kutsenko M. A., Chuchalin A. G. Comorbidity paradigm: syntropy of COPD and coronary artery disease.RMJ, 2014, vol. 5, p. 389. (In Russian)
Gurigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A. R., Lancellotti P., Patel A., DeCara J., Mitchell J., Harrison E., Moslehi J., Witteles R., Calabro M. G., Orecchia R., de Azambuja E., Zamorano J. L., Krone R., Iakobishvili Z., Carver J., Armenian S., Ky B., Cardinale D., Cipolla C. M., Dent S., Jordan K. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology, 2020. Vol. 31, no. 2, pp. 171–190.
Belialov F. I. Selection of medications in comorbidity. The Russian Archives of Internal Medicine, 2020,vol. 10, no. 1, pp. 161–169. (In Russian)
Shirinsky V. S., Shirinsky I. V. Comorbid diseases — an actual problem of clinical medicine. Siberian Journal of Clinical and Experimental Medicine, 2014, vol. 29, no. 1, pp. 7–12. (In Russian)
Gubanova G. V., Belyaeva Yu. N., Shemetova G. N. Comorbid patient: stages of formation, risk factors and tactics of management. Modern problems of science and education, 2015, vol. 6, pp. 60–77. (In Russian)
Belyalov F. I. Twelve theses of comorbidity. Clinical medicine, 2009, vol. 87, no. 12, pp. 69–71. (In Russian)
Gijsen R., Hoeymans N., Schellevis F. G., Ruwaard D., Satariano W. A., van den Bos G. A. Causes and consequences of comorbidity: A review. Clin. Epidemiol., 2001, vol. 54, no. 7, pp. 661–674.
Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine. Evidence Based Medicine,2010, vol. 15, no. 6, p. 165.
Gubanova G. V., Belyaeva Yu. N., Shemetova G. N. Comorbid patient: stages of formation, risk factors and tactics of management. Modern problems of science and education, 2015, vol. 6, pp. 60–77. (In Russian)
De Groot V., Beckerman H., Lankhorst G. J., Bouter L. M. How to measure comorbidity: A critical review of available methods. J. Clin. Epidemiol., 2003, vol. 56, no. 3, pp. 221–229.
Mark D., Miller M. D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, University of Pittsburgh, 1991, 31 p.
Deyo R. A., Cherkin D. C., Ciol M. A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol., 1992, vol. 45, no. 6, pp. 613–619.
Kaplan M. H., Feinstein A. R. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus. Diabetes, 1973, vol. 22, no. 3, pp. 74–160.
Greenfield S., Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: Comorbidity and outcomes after hip replacement. Med. Care, 1993, vol. 31, pp. 141–154.
Rozzini R., Frisoni G. B., Rozzini R. GeriatricIndex of Comorbidity: validation and comparisonwith other measures of comorbidity. Age Ageing, 2002, vol. 31, no. 4, pp. 85–277.
Groll D. L., To T., Bombardier C., Wright J. G. The development of a comorbidity index with physical function as the outcome. J. Clin. Epidemiol., 2005, vol. 58, no. 6, рр. 595–602.
Preedy V. R., Watson R. R. Handbook of Disease Burdens and Quality of Life Measures. New York,Springer, 2010.
Litwin M. S., Greenfield S., Elkin E. P. Assessment of Prognosis with the Total Illness Burden Index for Prostate Cancer. Cancer, 2007, vol. 109, no. 9, pp. 83–177.
Hall S. F. What is best comorbidity index for retrospective survival studies in head and neck oncology.Toronto, [s. n.], 2001, 135 p.
Komissarova S. M., Zakharova E. Yu., Sevruk Т. V., Ustinova I. B., Krasko O. V. Predictive value of the global longitudinal strain in hypertrophic cardiomyopathy patients. Russian Journal of Cardiology, 2018, no. 2, pp. 7–12. (In Russian)
Komajda M., Cosentino F., Ferrari R., Kerneis M., Kosmachova E., Laroche C., Maggioni A. P., Rittger H., Steg P. G., Szwed H., Tavazzi L., Valgimigli M., Gale C. P. Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. Eur. J. Cardiol., 2021, vol. 28, no. 4, pp. 432–445.
Van Manen J. G., Korevaar J. C., Dekker F. W., Boeschoten E. W., Bossuyt P. M., Krediet R. T. How to adjust for comorbidity in survival studies in ESRD patients: A comparison of different indices. American Journal of Kidney Diseases,2002, vol. 40, no. 1, pp. 82–89.
Hemmelgarn B. R., Manns B. J., Quan H., Ghali W. A. Adapting the Charlson comorbidity index for use in patients with ESRD. American Journal of Kidney Diseases, 2003, vol. 42, no. 1, Suppl. 2, pp. 125–132.
Daly C. A., De Stavola B., Fox K. M. Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: Prospective observational study. British Medical Journal, 2006, vol. 332, no. 7536, pp. 262–267.
Bhatt D. L., Steg P. G., Ohman E. M., Hirsch A. T., Ikeda Y., Mas J. L., Goto S., Liau C. S., Richard A. J., Röther J., Wilson P. W. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. J. Am. Med. Assoc., 2006, vol. 295, no. 2, pp. 180–189.
Sorbets E., Fox K. M., Elbez Y., Danchin N., Dorian P., Ferrari R., Ford I., Greenlaw N., Kalra P. R., Parma Z., Shalnova S., Tardif J. C., Tendera M., Zamorano J. L., Vidal-Petiot E., Steg P. G. Long-term outcomes of chronic coronary syndrome worldwide: Insights from the international CLARIFY registry. Eur. Heart J., 2020, vol. 41, no. 3, pp. 347–356.
Barbarash O. L., Kashtalap V. V., Shibanova I. A. Cardiovascular comorbidity: Patient with coronary artery disease and peripheral artery atherosclerosis. How to identify and manage the risks of ischemic events? Rational Pharmacotherapy in Cardiology, 2020, vol. 16, no. 4, pp. 607–613.
Zykov M. V., D’yachenko N. V., Trubnikova O. A., Erlih A. D., Kashtalap V. V., Barbarash O. L. Comorbidity and gender of patients at risk of hospital mortality after emergency percutaneous coronary intervention. Kardiologiya, 2020, vol. 60, no. 9, pp. 38–45. (In Russian)
Frolova Y. V., Sysoev S. Y., Tyurina E. A., Nikoda V. V., Zaytsev A. Y., Dymova O. V., Bedzhanyan A. L. Impact of comorbid chronic heart failure with preserved left ventricular ejection fraction on the management of elderly cancer patients before and after total resections. Khirurgiya. Zhurnal im. N. I. Pirogova, 2021, vol. 6, no. 2, pp. 45–51. (In Russian)
Yeh E. T. H., Bickford C. L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology, 2009, vol. 53, no. 24, pp. 2231–2247.
Palumbo A., Rajkumar S. V., Dimopoulos M. A., Richardson P. G., San Miguel J., Barlogie B., Harousseau J., Zonder J. A., Cavo M., Zangari M., Attal M., Belch A., Knop S., Joshua D., Sezer O., Ludwig H., Vesole D., Bladé J., Kyle R., Westin J., Weber D., Bringhen S., Niesvizky R., Waage A., von Lilienfeld-Toal M., Lonial S., Morgan G. J., Orlowski R. Z., Shimizu K., Anderson K. C., Boccadoro M., Durie B. G., Sonneveld P., Hussein M. A. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, vol. 22, no. 2, pp. 414–423.
Korzh A. Cardiorenal syndrome: clinical significance, diagnostic criteria, and principles of treatment.Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicine, 2016, vol. 2, pp. 37–42.
Rodrigo E., Pich S., Subirana I., Fernandez-Fresnedo G., Barreda P., Ferrer-Costa C., M. de Francisco Á. L., Salas E., Elosua R., Arias M. A clinical-genetic approach to assessing cardiovascular risk in patients with CKD. Clin. Kidney J., 2017, vol. 10, no. 5, pp. 672–678.
Easyan A. M. Chronic renal disease: risk factors, early detection, principles of antihypertensive therapy.Medical Council, 2017, no. 12, pp. 18–25.
Zueva T., Zhdanov T., Urazlina S. Comorbidity of renal and cardiac pathology. Medical news of the North Caucasus, 2019, vol. 14, no. 4, pp. 711–717.
United States Renal Data System. USRDS Annual Data Report. ESRD in the United States. 2018, vol. 2,pp. 183–598.
Collins A. J., Vassalotti J. A., Wang C., Li S., Gilbertson D. T., Liu J., Foley R. N., Chen S. C., Arneson T. J. Who Should Be Targeted for CKD Screening? Impact of Diabetes, Hypertension, and Cardiovascular Disease. American Journal of Kidney Diseases, 2009, vol. 53, no. 3, pp. S71–S77.
Morozova T. E., Popova T. S., Barabanova E. A., Samokhina E. O. The “Comorbid Patient” Scale as a General practitioner’s tool to increase treatment adherence in patients living in rural areas. Sechenov Medical Journal, 2021, vol. 11, no. 4, pp. 50–59. (In Russian)
Downloads
Published
2023-09-28
How to Cite
Blokhin, A. ., Shishkin, A. ., & Minkin, S. (2023). Methods for assessing comorbidity and its role in patients with cardiac pathology. Vestnik of Saint Petersburg University. Medicine, 18(2), 94–111. https://doi.org/10.21638/spbu11.2023.201
Issue
Section
Internal medicine
License
Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.
